Skip to main content
IMS Events Main banner

  1. Home

  • Thursday, Sep 18th
    12:08 - 12:14 East Coast USA Time
    (PA-488) Efficacy and Safety of a China-Developed BCMATargeted CAR-T Therapy (Eque-cel) in Plasma Cell Leukemia: Real-World Multicenter Experience
    Location: Room 714A
    Abstract Presenter: Jin Lu, Professor – Peking University People's Hospital
    Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
  • Friday, Sep 19th
    12:53 - 12:59 East Coast USA Time
    (PA-494) Outcomes in Second-Line Lenalidomide-Refractory Patients in the Phase 3 DREAMM-7 Study of Belantamab Mafodotin, Bortezomib (V), and Dexamethasone (d) vs Daratumumab-Vd in RRMM
    Location: Room 714A
    Abstract Presenter: Maria-Victoria Mateos, PhD (she/her/hers) – University Hospital of Salamanca
    Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
  • Saturday, Sep 20th
    09:00 - 09:10 East Coast USA Time
    (OA-58) Isatuximab Subcutaneous via an on-body Delivery System versus Isatuximab Intravenous, Plus Pomalidomide and Dexamethasone, in Relapsed/Refractory Multiple Myeloma: The Randomized Phase 3 IRAKLIA Study
    Location: Room 701
    Abstract Presenter: Xavier P. Leleu, MD, PhD (he/him/his) – Hospital La Mileterie, Poitiers, France
    Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
  • Saturday, Sep 20th
    09:10 - 09:20 East Coast USA Time
    (OA-54) Efficacy of Mezigdomide Plus Dexamethasone and Bortezomib or Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma by Line of Therapy: Results from the Phase 1/2 CC-92480-MM-002 Trial
    Location: Room 701
    Abstract Presenter: Albert Oriol, PhD (he/him/his) – Catalan Institute of Oncology and Josep Carreras Institute, Hospital Germans Trias i Pujol, Badalona, Spain
    Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
  • Saturday, Sep 20th
    09:20 - 09:30 East Coast USA Time
    (OA-57) IVIG and Longer Dosing Intervals Reduce Risk of Infections in Patients with RRMM Treated with Teclistamab
    Location: Room 701
    Abstract Presenter: Febe Smits, MD – Department of Hematology, Amsterdam UMC, Amsterdam, The Netherlands
    Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
  • Saturday, Sep 20th
    09:30 - 09:40 East Coast USA Time
    (OA-59) The Anti-BCMA Antibody-Drug Conjugate HDP-101 with a Novel Amanitin Payload Shows Promising Data in Relapsed/Refractory Multiple Myeloma in a Phase 1/2a Clinical Trial as it Advances into Cohort 7
    Location: Room 701
    Abstract Presenter: Jonathan L. Kaufman, MD – Winship Cancer Institute of Emory University
    Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
  • Saturday, Sep 20th
    09:40 - 09:50 East Coast USA Time
    (OA-53) Functional High-Risk (FHR) Phenotype Predicts Poor Survival in Multiple Myeloma (MM) Independent of Frontline Treatment: A Secondary CIBMTR Analysis
    Location: Room 701
    Abstract Presenter: Rahul Banerjee, MD (he/him/his) – Fred Hutchinson Cancer Center
    Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
  • Saturday, Sep 20th
    11:00 - 11:10 East Coast USA Time
    (OA-60) Updated Interim Results of Sonrotoclax + Dexamethasone in Patients With t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (R/R MM): An All-Oral Treatment
    Location: Room 701
    Abstract Presenter: Binod Dhakal, MD, MS – Medical College of Wisconsin
    Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
  • Saturday, Sep 20th
    11:10 - 11:20 East Coast USA Time
    (OA-52) Updated Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC® Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Location: Room 701
    Abstract Presenter: Binod Dhakal, MD, MS – Medical College of Wisconsin
    Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
  • Saturday, Sep 20th
    11:30 - 11:40 East Coast USA Time
    (OA-56) Belantamab for the Treatment of Multiple Myeloma: Results from Part 1 of the First-in-Human Phase 1/2 DREAMM-20 Trial
    Location: Room 701
    Abstract Presenter: Hang Quach, MBBS(Hons) FRACP FRCPA MD (she/her/hers) – St Vincent’s Hospital Melbourne, University of Melbourne, VIC, Australia
    Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
  • Saturday, Sep 20th
    11:40 - 11:50 East Coast USA Time
    (OA-55) Treatment Patterns and Outcomes in Quad-Class Exposed (QCE) Relapsed Refractory Multiple Myeloma (RRMM): Investigating Critical Unmet Needs
    Location: Room 701
    Abstract Presenter: Doris K. Hansen, MD – Department of Blood & Marrow Transplant and Cellular Immunotherapy (BMT CI), Moffitt Cancer Center
    Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)